Amniotic fluid formulation for treatment of joint pain or disorders
A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stemcells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on the severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft.
1. A method of treating or alleviating pain or inflammation associated with a disease, disorder, degeneration or injury of a joint or associated soft tissue in a subject suffering therefrom comprising administering to or adjacent to the joint or soft tissue in the subject an effective amount of a sterile, de-cellularized, filtered human amniotic fluid (D-HAF) devoid of amniotic stem cells, elements of micronized membrane, and chorion particles, sterilized only by filtration.
2. The method of claim 1 wherein the D-HAF is administered in a form selected from the group consisting of a solution, suspension and powder.
3. The method of claim 2 wherein the D-HAF is administered with an implant, prosthetic, suture, pin, screw or plate, or soft tissue repair device.
4. The method of claim 1 wherein the D-HAF is administered with a pharmaceutically acceptable carrier for injection.
5. The method of claim 1 wherein the D-HAF is administered in combination with one or more additional therapeutic, prophylactic or diagnostic agents.
6. The method of claim 5 wherein the D-HAF is administered in combination with one or more agents selected from the group consisting of antimicrobial agents, analgesic agents, local anesthetic agents, anti-inflammatory agents, anti-oxidant agents, immunosuppressant agents, anti-allergenic agents, enzyme cofactors, essential nutrients, growth factors, and combinations thereof.
7. The method of claim 1 wherein the disorder is selected from the group consisting of arthritis, bursitis, tendinitis, tenosynovitis, osteochondrosis, fibrous dysplasia, bone tumor, dislocations, and fractures.
8. The method of claim 7 wherein the disorder is osteoarthritis.
9. The method of claim 1 wherein the D-HAF promotes repair, and/or regeneration of cartilage.
10. The method of claim 1 wherein the subject is selected from the group consisting of human, dog, cat, cow, horse, and domestic livestock.